抗类风湿性关节炎新药的研究与开发进展_杜海洲.pdf

抗类风湿性关节炎新药的研究与开发进展_杜海洲.pdf

  1. 1、本文档共8页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
抗类风湿性关节炎新药的研究与开发进展_杜海洲

PROGRESS IN PHARMACEUTICAL SCIENCES 2014,3388 8 :733-740 733 R E V I E W A N D M O N O G R A P H    Latest Progress in Research and Development of New Anti-Rheumatoid Arthritis Drugs DU Haizhou ( Medical Library of the Chinese PLA, Beijing 100039, China) Based on the data in the reports published by the Pharmaceutical Research and Manufacturers of America (PhRMA), clinicaltrials. gov and other related new drug databases, the international clinical development of 34 new candidate drugs entering phase - clinical trials or receiving approval for rheumatoid arthritis (RA) in 2014 was statistically analyzed. Especially, 9 new candidate drugs entering phase clinical trials or receiving approval among them were classifi ed into synthetic (chemical) disease-modifying antirheumatic drugs (sDMARDs), biological original DMARDs (boDMARDs), biosimilar DMARDs (bsDMARDs) and therapeutic vaccine and were mainly reviewed. anti-rheumatoid arthritis drug; disease-modifying antirheumatic drug; therapeutic vaccine

文档评论(0)

yan698698 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档